Isoalantolactone and tabersonine can inhibit TRAF6 and thus inhibit the activation of the NF-κB signal pathway, and tabersonine can also inhibit the activation of the MAPK signal pathway and reduce the expression of macrophage pro-inflammatory cytokines in ALI induced by LPS, showing significant anti-inflammatory activity in ALI [65,72]. The gene discussed is NFKB1; the disease is acute respiratory distress syndrome.